Authors’ response: Addressing the blind spot of self-reported adherence in the era of long-acting PrEP

Davide Moschese; Andrea Antinori; Andrea Gori; Valentina Mazzotta; on behalf of the authors of the original article

doi:10.2807/1560-7917.ES.2026.31.2.2600010

Letter Open Access

Like 0

Download

Authors’ response: Addressing the blind spot of self-reported adherence in the era of long-acting PrEP
Davide Moschese¹ , Andrea Antinori^2,3 , Andrea Gori^1,4,5 , Valentina Mazzotta² , on behalf of the authors of the original article⁶
View Affiliations Hide Affiliations

Affiliations: ¹ Department of Infectious Diseases, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy ² Regional AIDS Reference Center, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy ³ Health Direction, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy ⁴ Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy ⁵ Centre for Multidisciplinary Research in Health Science (MACH) , Milan, Italy ⁶ https://doi.org/10.2807/1560-7917.ES.2025.30.39.2500739

Correspondence:
Valentina Mazzotta
valentina.mazzotta inmi.it
View Citation Hide Citation

Citation style for this article: Moschese Davide, Antinori Andrea, Gori Andrea, Mazzotta Valentina, on behalf of the authors of the original article. Authors’ response: Addressing the blind spot of self-reported adherence in the era of long-acting PrEP. Euro Surveill. 2026;31(2):pii=2600010. https://doi.org/10.2807/1560-7917.ES.2026.31.2.2600010 Received: 07 Jan 2026; Accepted: 13 Jan 2026

Preview this article:

There is no abstract available.

This work is licensed under a Creative Commons Attribution 4.0 International License.

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.2.2600010

2026-01-15

2026-02-08

Click here for cited by

/content/10.2807/1560-7917.ES.2026.31.2.2600010

Full text loading...

/deliver/fulltext/eurosurveillance/31/2/eurosurv-31-2-8.html?itemId=/content/10.2807/1560-7917.ES.2026.31.2.2600010&mimeType=html&fmt=ahah

References

Landovitz RJ, Tao L, Yang J, de Boer M, Carter C, Das M, et al. Type 1 human immunodeficiency virus (HIV-1) incidence, adherence, and drug resistance in individuals taking daily emtricitabine/tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: pooled analysis from 72 global studies. Clin Infect Dis. 2024;79(5):1197-207. https://doi.org/10.1093/cid/ciae143 PMID: 38484128
European AIDS Clinical Society (EACS). EACS Guidelines version 13.0. Brussels: EACS; 2025. Available from: https://www.eacsociety.org/guidelines/eacs-guidelines
Zeballos D, Guimarães NS, Pereira M, Magno L, Dourado I. Performance of adherence measures for oral, tenofovir-based HIV pre-exposure prophylaxis: a systematic review. AIDS Behav. 2025;29(9):2841-54. https://doi.org/10.1007/s10461-025-04741-8 PMID: 40327271
Mazzotta V, Caruso E, Tavelli A, Esvan R, Lanini S, Micheli G, et al. HIV oral pre-exposure prophylaxis effectiveness, adherence, and discontinuation in an Italian multicentric access program: ItaPrEP Study. Open Forum Infect Dis. 2025;12(9):ofaf539. https://doi.org/10.1093/ofid/ofaf539 PMID: 40980566
Pyra M, Rusie L, Castro M, Keglovitz Baker K, McNulty M, Bohm N, et al. A taxonomy of pragmatic measures of HIV preexposure prophylaxis use. AIDS. 2020;34(13):1951-7. https://doi.org/10.1097/QAD.0000000000002618 PMID: 33009011
National Institute for Health and care Excellence (Nice). Cabotegravir for preventing HIV-1 in adults and young people; Technology appraisal guidance. Reference number:TA1106. Manchester: NICE. [Accessed: 2 Jan 2026]. Available from: https://www.nice.org.uk/guidance/ta1106

Submit comment

Comment moderation successfully completed

Submit your article here

Submit an Article

Authors’ response: Addressing the blind spot of self-reported adherence in the era of long-acting PrEP

Click here for cited by